Loading...
Back to narrative

COPN: EU Authorization And Launch Partnership Are Expected To Support Balanced Outlook

Expanding AI Diagnostics And Drug Platforms Will Navigate Regulatory Challenges

COPN logo
COPN
AnalystConsensusTarget
Not Invested
Published 17 Mar 2025

Update shared on 09 Dec 2025

Fair value Increased 0.13%
Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
65.1%
7D
0.2%

Analysts have nudged their price target for Cosmo Pharmaceuticals slightly higher to approximately $98.72 per share from about $98.59, citing expectations for stronger revenue growth that more than offset a modestly lower projected profit margin and valuation multiple.

What's in the News

  • European Commission grants Marketing Authorization for Winlevi clascoterone 10 mg/g cream for treatment of acne vulgaris in adults and adolescents aged 12 to under 18 years, with adolescent use restricted to facial application EU Marketing Authorization
  • Approval follows a positive CHMP opinion issued on August 25, 2025, confirming regulatory momentum for Cosmo Pharmaceuticals dermatology portfolio EU Marketing Authorization
  • Commercial launch of Winlevi to be led by partner Glenmark Pharmaceuticals across 15 European countries, including France, Spain, the Netherlands, and the Nordics, expanding Cosmo Pharmaceuticals geographic reach EU Marketing Authorization

Valuation Changes

  • Fair Value Estimate has risen slightly to CHF 98.72 from CHF 98.59 per share, reflecting a marginal upward revision to intrinsic value.
  • Discount Rate is effectively unchanged at 4.57 percent, indicating a stable risk assessment and cost of capital assumption.
  • Revenue Growth has increased meaningfully to 15.55 percent from 14.38 percent, signaling stronger expectations for top line expansion.
  • Net Profit Margin has edged down slightly to 42.51 percent from 42.58 percent, suggesting a modestly less favorable profitability outlook.
  • Future P/E multiple has decreased moderately to 15.10 times from 15.59 times, implying a slightly lower valuation applied to projected earnings.

Have other thoughts on Cosmo Pharmaceuticals?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.